Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JAK Inhibitor in Anti-MDA5+ Dermatomyositis
NCT04966884Phase 4Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tofacitinib oral solution in dermatomyositis (DM), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Total Improvement Score at 12 months. Status: unknown.
02
Drugs
tofacitinib oral solution
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT04966884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04966884.